News & Media
Our Microbiome Determines balanced health
Our Microbiome Determines balanced health
MD Healthcare announced on the 18th
of November that it was selected as a technology innovation task in the second
half of the BIG3 field of SME (Small Medium Enterprise) innovative growth
support project managed by the Ministry of SMEs and Startups.
Among the three new industrial fields, the
development technology is 'CMC and non-clinical research of MDH-101, a
candidate for treating respiratory inflammatory diseases.' Through this
project, development of a therapeutic for respiratory diseases such as viral
pneumonia will begin in earnest.
The project period is from January 2021 to
December 2022 and financial support will be approximately $540,000 (600 million
KRW).
A new microbial drug using microbe-derived
extracellular vesicles is a first-in-class drug worldwide and is the first
candidate material of its kind developed by Korea in the world.
Through this project, the MD Healthcare
research team will complete a pre-clinical test of the substance for treating
respiratory diseases such as pneumonia caused by respiratory viruses like
coronavirus using extracellular vesicles derived from microorganisms to prepare
for and promote clinical trial entry.